Monsanto had bought 3.3 million shares in Ceres's E round last year at $6.50 per share following a $137m collaboration signed in 2002 applying genomics technologies to identify genes that provide improvements in corn, soybean and certain other row crops, according to its regulatory filing.

In March, Solazyme aimed to raise $100m but now said it would issue 11.5 million shares, including 1.5 million if demand is strong enough as a so-called greenshoe allotment, at between $15 and $17 each. At the top end of its pricing range, Solazyme would have an initial market capitalisation of $965m.

Fusion-io will issue 10.76 million shares with its owners selling 1.5 million at up to $15 each, before 1.85 million shares can be sold if demand is strong enough.

LinkedIn's shares closed at $94.25 each after the initial public offering of $45 per share and more than doubling its market capitalization to $8.9bn.

Investment banks and shareholders Morgan Stanley, Citigroup and Credit Suisse are underwriting Bats's initial public offering.

Softbank diluted to 34.2% after RenRen's initial public offering, having originally invested $100m in April 2008, according to data provider Zero2IPO. By December last year, Softbank had invested $315m to give a six times return on the book value of its holding at $14 per share, Zero2IPO added.

Four investors have agreed to back Shanghai Pharmaceuticals with $550m to support its initial public offering. Pfizer and Bank of China will each invest $50m, Singapore state-backed Temasek will buy $300m of shares and Malaysia-based conglomerate Guoco Group the remaining $150m.

After more than three months of deliberations, LinkedIn, a social network for 100 million business people, has picked New York Stock Exchange for its flotation.